Post by Antonio FACCIORUSSO

https://lnkd.in/dK36wc8C Our SRMA of individual patient data confirms that in patients with unresectable MHBO, SEMSs offer superior stent patency and survival compared to PSs, with similar safety and procedural success. * Data from five RCTs comprising 322 patients were included. * SEMSs significantly improved stent patency (HR, 0.49; 95% CI, 0.35-0.68) and overall survival (HR, 0.60; 95% CI, 0.47-0.78) compared to PSs. * Reintervention was lower with SEMSs (RR, 0.76; 95% CI, 0.59-0.97). * No significant differences were found in technical and clinical success rates, or in AE rates. Mohammad Al Hayek Mouen Khashab Marco Spadaccini Ammar F. Mohamedhen Vall Nounou Muhammed Elhadi Alberto Larghi John Vargo MD, MBA, MPH, MASGE Cesare Hassan Douglas G. Adler, MD